Étiquette : Immunology

HORIANA

by jbertholdin Biotech, Institutions, Service Providers & others, Pharma

HORIANA

About the company

HORIANA is a premier consulting company dedicated to epidemiology and biostatistics, specializing in designing and conducting Healthcare Real-World Studies.

Established by a team of seasoned experts, each with over 15 years of experience in Life Sciences, Horiana is at the forefront of providing comprehensive support to its clients. With a dedicated team of more than 25 experts, Horiana is well-positioned to assist clients at every phase of their projects. Their clients span both private and public/academic healthcare professionals.

At HORIANA, they are committed to excellence and quality, ensuring the success of their clients’ projects.

About the solution

Their main solutions are:

– Expertise and Consulting: Specialized guidance in epidemiology, pharmacoepidemiology, and biostatistics/data science.
– Clinical and Observational Studies (on primary and secondary)
– Enriched Studies: Integration of data from diverse sources through multisource studies and linked studies.
– Evidence Synthesis: Conducting External Comparators such as Network Meta-Analysis (NMA) and Matching-Adjusted Indirect Comparison (MAIC).
– Synthetic Control Groups: Implementation of Synthetic Control Groups and External Control Arms.
– Training Programs: Certified QUALIOPI training center in Statistics & Epidemiology
– IDMC, DSMB and Strategic consulting

Website
Key information

–  Therapeutic areas: Biostatistics, Epidemiology & Data Science provider

–  Based in: Bordeaux, Grenoble (FRANCE) San Francisco (US)

–  Employees: 11 – 50

– Created in: 2021

IKTOS

by jbertholdin Biotech, Digital Health, Pharma

IKTOS

About the company

Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

About the solution

Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers the possiblity to its partners to use it unique technology via proprietary SaaS software platforms: Makya for de novo generative design and Spaya for retrosynthesis and synthetic access. Its partners can also rely on Iktos expertise to run integrated drug discovery projects from hit discovery, hit-to-lead, lead optimization, all the way down to preclinical drug candidate.

Website
Key information

–  Therapeutic areas: Any therapeutic areas including oncology, CNS / neurology, Immunology, Infectious diseases, Rare diseases

–  Based in: Headquarters and lab: Paris (FRANCE)
Additional offices: US and JAPAN

–  Employees: 51 – 200

– Created in: 2016

CONTACT
Bose AvirupChief Business Officer

avirup.bose@iktos.com

AQEMIA

by jbertholdin Biotech, Pharma

AQEMIA

About the company

AQEMIA is a next-gen pharmatech company generating one of the world’s fastest-growing drug discovery pipeline. Their mission is to design fast innovative drug candidates for dozens of critical diseases.

About the solution

Their differentiation lies in their unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates, with already several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies.

Website
Key information

–  Therapeutic areas: Oncology, Immunology, Inflammation, Central Nervous System, Metabolism

–  Based in: Paris (FRANCE)

–  Employees: 51 – 200

– Created in: 2019